Pediatric ANCA Associated-vasculitis

University Hospital, Strasbourg, France500 enrolled

Overview

The incidence in pediatrics is very low (about 0.5 per million according to a French study) and therefore the data on the pathology very poor, especially on the therapeutic level. Without appropriate treatment, the mortality rate of the pathology is very high. Existing treatments are almost exclusively composed of immunomodulatory and/or immunosuppressive treatments. Complications related to pathology and iatrogeny are among the first causes of mortality from this pathology and deserve to be studied in order to be known and if possible avoided. The purpose of the study is to achieve a national comparison of clinical and therapeutic practices.

Study Type

OBSERVATIONAL

Enrollment

500

Conditions

ANCA-Associated Vasculitis

Eligibility

Sex: ALLMin age: 1 YearMax age: 17 Years

Medical Language ↔ Plain English

Inclusion criteria: * Minor subject (\<18 years old) * Diagnosis of ANCA vasculitis according to the international criteria for defining the pathology, GPA or MPA form between 2011 and 2020. * Subject (and/or his parental authority) who has not expressed, after being informed, his opposition to the reuse of his data for the purposes of this research. Exclusion criteria: * Subject (or his parents) having expressed his (their) opposition to participating in the study * Patients with vasculitis has ANCA in the form of EGPA * Associated pathologies that cannot be related to the diagnosis of ANCA vasculitis and whose prognosis can lead to biases in the efficacy and/or complications related to treatments.

Locations (1)

Service de Pédiatrie 1 - CHU de Strasbourg - France

Strasbourg, France

RECRUITING

Outcomes

Primary Outcomes

Retrospective study of clinical and therapeutic practices at the national level.

Time frame: Files analysed retrospectively from January 01, 2011 to December 31, 2020 will be examined]

Central Contacts

Ariane ZALOSZYC, MD

CONTACT

33 3 88 12 77 49 ariane.zaloszyc@chru-strasbourg.fr

Saïd CHAYER, PhD, HDR

CONTACT

said.chayer@chru-strasbourg.fr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.